Semaglutide has transformed obesity and diabetes care, offering significant weight loss and glucose control with once-weekly dosing. Here’s a look at its clinical promise and expanding role in medicine.
Chronic pain is a crippling illness that significantly lowers quality of life and frequently results in a dependence on opioid drugs, which have serious adverse [Read More…]
A significant step in Alzheimer’s care: The FDA’s updated approval for the Amyvid PET scan allows for better diagnosis and patient selection for the latest amyloid-based treatments
AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.
Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in Phase 3 clinical trials. The innovative treatment demonstrated A1C reductions comparable to daily basal insulins, with a consistent safety profile.
Novo Nordisk has announced compelling results from its phase 3b STEP UP clinical trial, demonstrating that a higher 7.2 mg dose of its weight-loss medication, Wegovy® (semaglutide), led to a significant average weight loss of 21% in adults with obesity.
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as the first and only targeted biologic treatment for adults with bullous pemphigoid, a rare and debilitating autoimmune skin disease.
AbbVie reported strong results from a Phase 3 head-to-head trial, showing that atogepant (as QULIPTA®/AQUIPTA®) was superior to topiramate on all primary and secondary measures [Read More…]
Eli Lilly and Company declared today that Zepbound (tirzepatide), a popular weight-loss drug, will soon be offered in single-dose vials via LillyDirect Self Pay Pharmacy [Read More…]
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
